[ Do Not Miss ] 7 Mid-Cap Stocks That Are Trending Right Now

See which stocks have been rated by 3 or more analysts in the last few days. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Wall Street Legend Warns "Financial Reset" is Coming]( A historic event in 2023 could soon result in a run on the banks. Get out of cash and into a new vehicle 50 years in the making. --------------------------------------------------------------- December 19, 2022 From the desk of the Editor (Trending Mid-Cap Report) Dear Reader, We just identified 7 Mid-Cap stocks that have above average price targets according to the firms listed below. Today’s report includes Analyst coverage from the following firms; Cowen & Co., Mizuho Securities, Citigroup, J.P. Morgan, Needham, and RBC Capital. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- Sponsor Message [New Documentary: The Two Men Destroying America]( This is causing a lot of controversy… It’s a new documentary called [The Two Men Destroying America.]( And a lot of powerful people would rather this exposé never saw the light of day. Chances are, they’ll attempt to have it scrubbed from existence. That’s because it tells the true (and terrifying) story of how two men from New York have engineered a reset of not just your personal wealth, but the entire US economic system. [Click play to watch The Two Men Destroying America]( --------------------------------------------------------------- [Guardant Health, GH]( Recent Analyst Action: Max Masucci, analyst at Cowen & Co., reiterates coverage on [Guardant Health (GH)](in the Healthcare sector with a Buy rating and a price target of $70.00 (3 days ago). - Recent Price: $30.57 - Average Analyst Price Target: $70.21 (129.67%) - Market Cap: $3.08B [TipRanks.com]( also reports that [Guardant Health](currently has 14 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $70.21. The target pricing ranges from a high forecast of $90.00 down to a low forecast of $50.00. [Guardant Health (GH)](’s last closing price was $30.57 which would put the average price target at $70.21. Here are 3rd party ratings for [GH](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 26% (64 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [These 2 Dividend Stocks Pay Every Week]( you still looking for consistent income in this near-zero interest rate environment? There is a better way. I just revealed the Holy Grail of dividend stocks - a safe, reliable and consistent stock that [pays dividends EVERY single week](- 52 times a year. It's simple: Buy the stock this Monday and you'll get your first dividend payout in your bank account this Thursday....and then every Thursday after for as long as you own the stock! [Tap here to reveal the name of this stock for FREE.]( --------------------------------------------------------------- [Cytokinetics, CYTK]( Recent Analyst Action: Salim Syed, analyst at Mizuho Securities, reiterates coverage on [Cytokinetics (CYTK)](in the Healthcare sector with a Buy rating and a price target of $80.00 (3 days ago). - Recent Price: $43.83 - Average Analyst Price Target: $63.70 (45.33%) - Market Cap: $4.14B [TipRanks.com]( also reports that [Cytokinetics](currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $63.70. The target pricing ranges from a high forecast of $80.00 down to a low forecast of $47.00. [Cytokinetics (CYTK)](’s last closing price was $43.83 which would put the average price target at $63.70. Here are 3rd party ratings for [CYTK](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 26% (64 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [Jabil Circuit, JBL]( Recent Analyst Action: Jim Suva, analyst at Citigroup, reiterates coverage on [Jabil Circuit (JBL)](in the Technology sector with a Buy rating and a price target of $85.00 (3 days ago). - Recent Price: $68.31 - Average Analyst Price Target: $80.50 (17.85%) - Market Cap: $9.30B [TipRanks.com]( also reports that [Jabil Circuit](currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $80.50. The target pricing ranges from a high forecast of $92.00 down to a low forecast of $72.00. [Jabil Circuit (JBL)](’s last closing price was $68.31 which would put the average price target at $80.50. Here are 3rd party ratings for [JBL](: - TipRanks.com: Strong Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 1% (4 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Trader predicts HUGE Tesla shocker (go here to see)]( why he’s telling everyone around him to take action before April 25, 2023. [Go here to see this now.]( --------------------------------------------------------------- [Glaukos, GKOS]( Recent Analyst Action: Allen Gong, analyst at J.P. Morgan, reiterates coverage on [Glaukos (GKOS)](in the Healthcare sector with a Hold rating and a price target of $42.00 (10 hours ago). - Recent Price: $42.45 - Average Analyst Price Target: $57.71 (35.95%) - Market Cap: $2.03B [TipRanks.com]( also reports that [Glaukos](currently has 7 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $57.71. The target pricing ranges from a high forecast of $69.00 down to a low forecast of $42.00. [Glaukos (GKOS)](’s last closing price was $42.45 which would put the average price target at $57.71. Here are 3rd party ratings for [GKOS](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 36% (90 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [MKS Instruments, MKSI]( Recent Analyst Action: James Ricchiuti, analyst at Needham, reiterates coverage on [MKS Instruments (MKSI)](in the Industrial Goods sector with a Buy rating and a price target of $110.00 (4 days ago). - Recent Price: $77.97 - Average Analyst Price Target: $103.89 (33.24%) - Market Cap: $5.47B [TipRanks.com]( also reports that [MKS Instruments](currently has 9 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $103.89. The target pricing ranges from a high forecast of $145.00 down to a low forecast of $80.00. [MKS Instruments (MKSI)](’s last closing price was $77.97 which would put the average price target at $103.89. Here are 3rd party ratings for [MKSI](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Strong Sell, Bottom 4% (237 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast: ["Prepare for Five Years of Famine"]( [Click here]( for the name of the one ticker you need to protect yourself. --------------------------------------------------------------- [Maxar Technologies, MAXR]( Recent Analyst Action: Kenneth Herbert, analyst at RBC Capital, reiterates coverage on [Maxar Technologies (MAXR)](in the Technology sector with a Hold rating and a price target of $53.00 (10 hours ago). - Recent Price: $51.49 - Average Analyst Price Target: $48.33 (-6.14%) - Market Cap: $3.87B [TipRanks.com]( also reports that [Maxar Technologies](currently has 9 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $48.33. The target pricing ranges from a high forecast of $53.00 down to a low forecast of $22.00. [Maxar Technologies (MAXR)](’s last closing price was $51.49 which would put the average price target at $48.33. Here are 3rd party ratings for [MAXR](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 28% (70 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [Blueprint Medicines, BPMC]( Recent Analyst Action: Ami Fadia, analyst at Needham, reiterates coverage on [Blueprint Medicines (BPMC)](in the Healthcare sector with a Buy rating and a price target of $60.00 (5 days ago). - Recent Price: $43.39 - Average Analyst Price Target: $81.62 (88.11%) - Market Cap: $2.71B [TipRanks.com]( also reports that [Blueprint Medicines](currently has 15 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $81.62. The target pricing ranges from a high forecast of $114.00 down to a low forecast of $52.00. [Blueprint Medicines (BPMC)](’s last closing price was $43.39 which would put the average price target at $81.62. Here are 3rd party ratings for [BPMC](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 26% (64 out of 248) [Click here for chart >>]( ------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message Friends… On October 27, the CEO of New England’s largest energy company sent a desperate letter to the White House. ["This represents a serious public health and safety threat,"](Eversource CEO Joe Nolan wrote in a letter to President Joe Biden. He then begged Joe Biden to use the federal government's emergency powers to make sure natural gas will be available in New England this winter. There’s only one problem. There’s nothing Biden or anyone can do at this point. All available natural gas is on its way to Europe. When large parts of New England go dark and freeze this winter, a lot of people will call it a shocking natural disaster. Or they’ll say it was because Russia invaded Ukraine. But cities don’t go dark and freeze in the wealthiest country in the world by accident. My name is Porter Stansberry. I’m the founder of one of the world’s largest financial research firms. I’ve spent the last two years researching this coming crisis. I’ve been writing about it in my newsletter, The Big Secret on Wall Street, since June… And now that this crisis is set to unfold, exactly the way I’ve been predicting, I’ve uploaded an eye-opening video that tells the whole sordid tale. I name names in it. And I reveal who caused this crisis, and why… Do yourself a favor. Before it’s taken offline – which could happen at any time – check out this [shocking video](. I’ve seen in the past just how far powerful people will go to silence me. Don’t miss this: [CLICK HERE.]( --------------------------------------------------------------- And there you have it--7 Mid-Cap Stocks that are getting attention from some of Wall Street Top Analysts. Sincerely, The Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software